Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS7 | Q9UKP4 | 1/20 | 0.56 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.56 |
| ▸ | MMP1 | P03956 | 10/20 | 0.54 |
| ▸ | MMP13 | P45452 | 10/20 | 0.54 |
| ▸ | MMP9 | P14780 | 9/20 | 0.54 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.49 |
| ▸ | MMP2 | P08253 | 6/20 | 0.47 |
| ▸ | MMP3 | P08254 | 6/20 | 0.47 |
| ▸ | MMP7 | P09237 | 4/20 | 0.47 |
| ▸ | MMP8 | P22894 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6291014 | 0.92 | MMP13 (0.54) | MMP1MMP13MMP9ADAM17OPRM1 | |
| SCHEMBL7250654 | 0.90 | ADAMTS7 (0.71) | ADAMTS7ADAMTS5MMP1MMP13MMP9 | |
| SCHEMBL6808793 | 0.87 | ADAMTS7 (0.56) | ADAMTS7ADAMTS5MMP1MMP13MMP9 | |
| SCHEMBL6809689 | 0.83 | MMP13 (0.56) | ADAMTS7ADAMTS5MMP1MMP13MMP9 | |
| SCHEMBL6289783 | 0.82 | MMP3 (0.61) | ADAMTS7ADAMTS5MMP1MMP13MMP9 | |
| SCHEMBL6810070 | 0.80 | MMP13 (0.66) | ADAMTS7ADAMTS5MMP1MMP13MMP9 | |
| SCHEMBL6291040 | 0.79 | MMP13 (0.55) | MMP1MMP13MMP9MMP2MMP3 | |
| SCHEMBL6372187 | 0.77 | MMP13 (0.60) | ADAMTS7ADAMTS5MMP1MMP13MMP9 | |
| SCHEMBL6291016 | 0.77 | MMP13 (0.67) | MMP1MMP13MMP9ADAM17OPRM1 | |
| SCHEMBL7251477 | 0.75 | ADAMTS7 (0.71) | ADAMTS7ADAMTS5MMP1MMP13MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127498-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2004-07-01 | — | — | US | claimed |
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | THE PROCTER & GAMBLE COMPANY | 2003-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139414-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | ADAMTS7 90/4885ADAMTS5 87/4885MMP1 15/4885 |
| US-20040127498-A1 | Heterocyclic side chain containing, n-substituted metalloprotease inhibitors | MME, MMP2, MMP9 | ADAMTS7 90/4885ADAMTS5 87/4885MMP1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.